Covid-19 vaccine developer BioNTech attracts Temasek investment
German biotechnology company BioNTech has raised $225m via a private placement led by Singaporean sovereign wealth fund Temasek, amid growing investor appetite for biotech investments due to the Covid-19 pandemic.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: